Effects of insulin-like growth factor-binding protein 2 and an IGF-type I receptor-blocking antibody on apoptosis in human teratocarcinoma cells in vitro

Cell Biol Int. 2001;25(8):825-8. doi: 10.1006/cbir.2001.0756.

Abstract

Human teratocarcinoma cells (Tera-2) deprived of serum undergo programmed cell death which can be counteracted by simultaneous addition of IGF-I or IGF-II. This protective effect of IGFs was specific in the sense that both addition of IGF-binding protein-2, and blocking of the IGF-type I receptor by a specific antibody, both resulted in an increased apoptotic rate.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antibodies / pharmacology*
  • Apoptosis / drug effects*
  • Cell Count
  • Cell Division / drug effects
  • Dose-Response Relationship, Drug
  • Humans
  • Insulin-Like Growth Factor I / pharmacology
  • Insulin-Like Growth Factor II / pharmacology*
  • Receptor, IGF Type 1 / immunology*
  • Teratocarcinoma / pathology*
  • Teratocarcinoma / prevention & control
  • Time Factors
  • Tumor Cells, Cultured / cytology
  • Tumor Cells, Cultured / drug effects

Substances

  • Antibodies
  • Insulin-Like Growth Factor I
  • Insulin-Like Growth Factor II
  • Receptor, IGF Type 1